XHKG
8372
Market cap17mUSD
Oct 09, Last price
0.17HKD
1D
0.00%
1Q
21.58%
IPO
-48.79%
Name
Grand Brilliance Group Holdings Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Grand Brilliance Group Holdings Limited, an investment holding entity, primarily operates by distributing medical equipment and related items across Hong Kong. Its extensive product portfolio encompasses various medical supplies, including disposables, specialized instruments, and advanced medical machinery. The company also undertakes the development of innovative healthcare products. Beyond product distribution, it delivers comprehensive medical device solutions such as in-depth market trend assessments, strategic sourcing, post-sale support, technical training, equipment rental, and stringent quality assurance. Additionally, the firm manages maintenance services and holds several registered trademarks. Its diverse client base spans both public and private healthcare facilities, independent clinics, charitable groups, academic institutions, and direct consumers. Established in 1997, the company is headquartered in Tsuen Wan, Hong Kong, and operates as a subsidiary of B&A Success Limited.
Key people
Bik Kwan Wong
Chairman, Chief Executive Officer, Chief Compliance Officer, Executive Director · since 2017
Hoi Yin Ho
General Manager · since 2021
Chi Chong Cheung
Financial Controller · since 2019
Wai Man Lau
Manager in Marketing, project and service engineering · since 2018
Chun Sing Lee
Business Development Manager · since 2014
Ka Man Lee
Company Secretary · since 2019
Man Wai Chiu
Non-Executive Director · since 2017
Yin Shun Miu
Non-Executive Director · since 2017
Fan Wa Chiu
Independent Non-Executive Director · since 2025
Ming Po Chow
Independent Non-Executive Director · since 2021
Independent Non-Executive Director · since 2018
IPO date
Mar 29, 2018
Employees
41
Domiciled in
HK
Incorporated in
KY
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||